144 related articles for article (PubMed ID: 12230858)
1. Who are the guardians guarding?
Trachtman H
Am J Bioeth; 2002; 2(3):46-8. PubMed ID: 12230858
[No Abstract] [Full Text] [Related]
2. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
3. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
4. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
5. Beyond government intervention: drug companies and bioethics.
Dresser R
Am J Bioeth; 2002; 2(3):42-3. PubMed ID: 12230855
[No Abstract] [Full Text] [Related]
6. Not taking, just borrowing: government use of patented drugs.
Ossorio PN
Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
[No Abstract] [Full Text] [Related]
7. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
8. Patents: the public interest versus the private privilege.
Parsi KP; Egan EA
Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
[No Abstract] [Full Text] [Related]
9. Life, death, and monopoly rights in a democratic society.
Smith SJ
Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856
[No Abstract] [Full Text] [Related]
10. Bioterrorism, public health, and international law.
Fidler DP
Chic J Int Law; 2002; 3(1):7-26. PubMed ID: 15709296
[No Abstract] [Full Text] [Related]
11. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
12. The burgeoning science of genetics and the impact on public policy.
Hatch OG
J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088
[TBL] [Abstract][Full Text] [Related]
13. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
14. Response to commentaries : Resnik, D. B. and K. A. DeVille. 2002. "Bioterrorism and patient rights: 'compulsory licensure' and the case of Cipro." The American Journal of Bioethics 2(3): 29-39.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(4):W1. PubMed ID: 12816075
[No Abstract] [Full Text] [Related]
15. Patent crunch pending.
Wadman M
Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
[No Abstract] [Full Text] [Related]
16. Promega changes tack in battle over patent.
Knight J
Nature; 2003 Nov; 426(6965):373. PubMed ID: 14647346
[No Abstract] [Full Text] [Related]
17. Bioterrorism, public health, and civil liberties.
Annas GJ
N Engl J Med; 2002 Apr; 346(17):1337-42. PubMed ID: 11973377
[No Abstract] [Full Text] [Related]
18. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
19. Washington Insider: Congressional impasse on human cloning.
Doerflinger RM
Natl Cathol Bioeth Q; 2004; 4(1):19-25. PubMed ID: 15192847
[No Abstract] [Full Text] [Related]
20. Biomedical patents and the public's health: is there a role for eminent domain?
Kesselheim AS; Avorn J
JAMA; 2006 Jan; 295(4):434-7. PubMed ID: 16434634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
